Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure

European Heart Journal

Volumn 31, Issue 14, 2010, Pages 1752-1763

  Núñez, Julio ^a   Sanchis, Juan ^a   Bodí, Vicent ^a   Fonarow, Gregg C ^b   Núñez, Eduardo ^a   Bertomeu González, Vicente ^c   Miñana, Gema ^a   Consuegra, Luciano ^d   Bosch, Maria José ^e   Carratalá, Arturo ^f   Chorro, Francisco J ^a   Llcer, Angel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^d Hospital Virgen del Rosell   (Spain)

^e HOSPITAL DE LA PLANA   (Spain)

^f Hospital Clinico Universitario   (Spain)

Author keywords

Acute heart failure; Brain natriuretic peptide; Mortality; Tumour marker antigen carbohydrate 125

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN;

ACUTE HEART FAILURE; AGED; ARTICLE; CAUSE OF DEATH; DISEASE ASSOCIATION; FEMALE; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CA-125 ANTIGEN; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RISK ASSESSMENT;

EID: 77954794121     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq142     Document Type: Article

References (35)

1. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008;451:949-952.
2. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-1433.
3. Núñez J, Núñez E, Robles R, Bod́i V, Sanchis J, Carratalá A, Aparici M, Llàcer A. Prognostic value of brain natriuretic peptide in acute heart failure: mortality and hospital readmission. Rev Esp Cardiol 2008;61:1332-1337.
4. Cournot M, Mourre F, Castel F, Ferrières J, Destrac S. Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure. Am Heart J 2008;155: 986-991.
5. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee, Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007;49:1943-1950.
6. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-641.
7. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52: 1458-1465.
8. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from car-vedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781-1787.
9. Peacock WF IV, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH, ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-2126.
10. Núñez J, Núñez E, Consuegra L, Sanchis J, Bod́i V, Mart́inez-Brotons A, Bertomeu-González V, Robles R, Bosch MJ, Fácila L, Darmofal H, Llàcer A. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 2007;93:716-721.
11. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003;41:1805-1811.
12. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339: 321-328.
13. Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005;7:840-843.
14. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003;24:172-175.
15. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 2006;8:270-274.
16. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695-1707.
17. Remme WJ, Swedberg K, Task Force for the Diagnosis, Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
18. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Moreno R, Singer M, Singh S, Tendera M, Thygesen K, ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005;26:384-416.
19. Task Force for Diagnosis, Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29: 2388-2442.
20. American Heart Association. Heart disease and stroke statistics-2005 update. Dallas, TX: American Heart Association; 2005.
21. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007;26:5512-5528.
22. Fine J, Gray RJ. A proportional hazard model for the subdistribution of a competing risk. J Am Statist Assoc 1999;94:496-509.
23. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifica-tion and beyond. Stat Med 2008;27:157-172.
24. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882-890.
25. Cotter G, Felker GM, Adams KF, Milo-Cotter O, O'Connor CM. The pathophy-siology of acute heart failure-is it all about fluid accumulation? Am Heart J 2008; 155:9-18.
26. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-169.
27. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140: 840-847.
28. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005;7:199-203.
29. Nägele H, Bahlo M, Klapdor R, Rödiger W. Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 1999;19: 2531-2534.
30. Faggiano P, D'Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 2005;7:57-61.
31. Chen YX, Wang XQ, Fang CF, Wang JF, Tang LJ. Value of BNP and tumour marker CA125 in patients with heart failure. Acta Cardiol 2008;63:501-506.
32. Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000;15: 1261-1265.
33. Seo T, Ikeda Y, Onaka H, Hayashi T, Kawaguchi K, Kotake C, Toda T, Kobayashi K. Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 1993;57:489-494.
34. Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 2000;77:254-257.
35. Zeimet AG, Offner FA, Marth C, Heim K, Feichtinger H, Daxenbichler G,Dapunt O. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 1997;17:3129-3131.